Identification of objective markers for the evaluation and prediction of the treatment of children and adolescents with ADHD

Identification of objective markers for the evaluation and prediction of the treatment of children and adolescents with ADHD - MPH-Predict

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030766

Enrollment

150

Registered

2022-12-12

Start date

2023-03-03

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F90.0 F98.8 F90.1

Interventions

Group 1: Children/Adolescents with AD(H)S, who are prescribed Methylphenidate (MPH) or Children/adolescents with AD(H)S, after a break from medication (methylphenidate, =4 weeks) T0: - Parents: Chil

Eligibility

Sex/Gender

All

Age

8 Years to 16 Years

Inclusion criteria

Inclusion criteria: Children/adolescents with AD(H)D: 1. AD(H)D diagnosis according to ICD10/DMS-5 2. Children/adolescents aged 8 to 16 3. Written consent 4. Consent of parents/legal guardians 5. Persons who are legally competent and mentally able to follow the instructions of the staff Healthy controls: 1. Children/adolescents aged 8 to 16 2. Written consent 3. Consent of parents/legal guardians 4. Persons who are legally competent and mentally able to follow the instructions of the staff

Exclusion criteria

Exclusion criteria: Children/adolescents with AD(H)D: 1. IQ < 80 2. Diagnosed autism spectrum disorder, epilepsy or brain-organic damage 3. Persons who are placed in an institution by order of the authorities or the court 4. Persons who are in a dependent or employment relationship with the researcher Healthy controls: 1. IQ < 80 2. Diagnosed AD(H)D, autism spectrum disorder, epilepsy or brain-organic damage 3. Persons who are placed in an institution by order of the authorities or the court 4. Persons who are in a dependent or employment relationship with the researcher

Design outcomes

Primary

Measure	Time frame
Primary outcome will be response to MPH (8 weeks after completed dosing with MPH) Changes in: - Questionnaires (Conner's Rating Scales for parents, child, teachers; Children's Communication Checklist; Medication Adherence Rating Scale; Barkley Scale; Clinical Global Impression Scale; Line Listing) - Neuropsychological assessments (QbTest; Testbattery for attentional performance) - Language- and voice-related assessments (spontaneous speech; verbal fluency test (Regesburger Wortflüssigkeits-Test); phonological working memory (digit span; WISC-V)) - Movement and activity data (JTrack) - MRI; Follow up interview with parents by phone after three months	—

Measure

Time frame

Primary outcome will be response to MPH (8 weeks after completed dosing with MPH) Changes in: - Questionnaires (Conner's Rating Scales for parents, child, teachers; Children's Communication Checklist; Medication Adherence Rating Scale; Barkley Scale; Clinical Global Impression Scale; Line Listing) - Neuropsychological assessments (QbTest; Testbattery for attentional performance) - Language- and voice-related assessments (spontaneous speech; verbal fluency test (Regesburger Wortflüssigkeits-Test); phonological working memory (digit span; WISC-V)) - Movement and activity data (JTrack) - MRI; Follow up interview with parents by phone after three months

—

Secondary

Measure	Time frame
Prediction of treatment effect employing machine learning-based statistics	—

Countries

Germany

Contacts

Public ContactRachel Bamberger

Uniklinik RWTH AachenKlinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters

rbamberger@ukaachen.de0241-80-37050

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026